Literatur
- 1
Anderson W, Wisniewski M, Barbee R, Rickard K A.
Comparison of Serevent and ipratropium on pulmonary function in COPD patients reversible
to ipratropium.
Am J Respir Crit Care Med.
1997;
155
A277
- 2
Anthonisen N R, Connett J E, Kiley J P, Altose M D, Bailey W D. et al .
Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilatator
on the Rate of Decline of FEV1. The Lung Health Study.
JAMA.
1994;
272
1497-1505
- 3
ATS Statement .
Standards for the diagnosis and care of patients with chronic obstructive pulmonary
disease.
Am J Respir Crit Care Med.
1995;
152
S77-120
- 4
Barnes P J.
New therapies for chronic obstructive pulmonary disease.
Thorax.
1998;
53
137-147
- 5
Belman M J, Botnick W C, Shin J W.
Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients
with chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1996;
153
967-975
- 6
Bloch K E.
Lungenemphysem: Indikation zur chirurgischen Behandlung.
Schweiz Med Wochenschr.
1998;
128
442-450
- 7
Bourbeau J, Rouleau M Y, Boucher S.
Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive
pulmonary disease.
Thorax.
1998;
53
477-482
- 8
Boyd G, Morice A H, Pounsford J C, Siebert M, Peslis N, Crawford C.
An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease
(COPD).
Eur Respir J.
1997;
10
815-821
- 9
Brändli O.
Sind inhalierte Staubpartikel schädlich für unsere Lungen.
Schweiz Med Wochenschr.
1996;
126
2165-2174
- 10
Brian L T.
Disease management of COPD with pulmonary rehabilitation.
CHEST.
1997;
112
1630-1656
- 11
British Thoracic Society Statement .
COPD: summary of guidelines.
Thorax.
1997;
52 (Suppl 5)
S2-21
- 12
Brochard L, Mancebo J, Wysocki M, Lofaso F, Conti G. et al .
Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease.
NEJM.
1995;
333
817-822
- 13
Büchi S, Villiger B, Sensky T, Schwarz F, Wolf Ch, Buddeberg C.
Psychosocial predictors of long-term success of in-patient pulmonary rehabilitation
of patients with COPD.
Eur Respir J.
1997;
10
1272-1277
- 14
Burge P S.
EUROSCOP, ISOLDE and the Copenhagen city lung study.
Thorax.
1999;
54
287-288
- 15
Chambers D C, Tunnicliffe W S, Ayres J G.
Acute inhalation of cigarette smoke increases lower respiratory tract nitric oxide
concentrations.
Thorax.
1998;
53
677-679
- 16
Chanez P, Vignola A M, O'Shaugnessy R, Enander I, Li D, Jeffery P K, Bousquet J.
Corticosteroid reversibility in COPD is related to features of asthma.
Respir Crit Care Med.
1997;
155
1529-1534
- 17
COMBIVENT Inhalation Aerosol Study Group .
In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol
is more effective than either agent alone.
CHEST.
1994;
105
1411-1419
- 18
Confalonieri M, Mainardi E, Porta R D, Bernorio S, Bandola L, Beghè B, Spanevello A.
Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with
chronic obstructive pulmonary disease.
Thorax.
1998;
53
583-585
- 19
Doll R, Peto R, Wheatley K, Gray R, Sutherland I.
Mortality in relation to smoking: 40 years observation on male British doctors.
BMJ.
1994;
309
901-910
- 20
Gosselink R, Troosters T, Decramer M.
Exercise training in COPD patient: the basic questions.
Eur Respir J.
1997;
10
2884-2891
- 21
Hak E, Essen G A, Buskens E, Stalman W, de Melker R A.
Is immunising all patients with chronic lung disease in the community against influenza
cost effective.
J Epidem and Community Health.
1998;
52
120-125
- 22 Henningsfield J A. Nicotine medications for smoking cessation. N Engl J Med 1196-1203
- 23 Hess Th. Pneumokokken-Impfung - Ja oder Nein. Schweiz Med Wochenschr 1096-1103
- 24
Hillberg R E, Johnson D C.
Noninvasive Ventilation.
N Engl J Med.
1997;
337
1746-1752
- 25 Hurt R D, Sachs D PL, Glover E D. A comparison of sustained-release bupropion and
placebo for smoking cessation. N Engl J Med 1997 337
- 26
Ingenito E P, Evans R B, Loring S J, Kaczka D W, Rodenhouse J D, Body S C, Sugarbaker D J,
Mentzer S J, DeCamp M M, Reilly J J.
Relation between preoperative inspiratory lung resistance and the outcome of lung-volume-reduction
surgery for emphysema.
N Engl J Med.
1998;
338
1181-1185
- 27
Jeffery P K.
Structural and inflammatory changes in COPD: a comparison with asthma.
Thorax.
1998;
53
129-136
- 28
Joint ACCP/ACVPR Evidence-Based Guidelines: .
Pulmonary Rehabilitation.
CHEST.
1997;
112
1363-1396
- 29
Jones P W, Bosh T K. in association with an international study group .
Quality of life changes in COPD patients treated with Salmeterol.
Am J Respir Crit Care Med.
1997;
155
1283-1289
- 30
Keatings V M, Jatakanow A, Worsdell Y M, Barnes P J.
Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and
COPD.
Am J Respir Crit Care Med.
1997;
155
542-548
- 31
Köhler D, Criée C, Raschke F. et al .
Leitlinien zur häuslichen Sauerstoff- und Heimbeatmungstherapie.
Med Klinik.
1997;
92
2-6
- 32
Koyama H, Geddes D M.
Genes, oxidative stress, and the risk of chronic obstructive pulmonary disease.
Thorax.
1998;
53 (Suppl 2)
S10-S14
- 33
Langley S J, Masterson C M, Batty E P, Woodcock A.
Bronchodilator response to salbutamol after chronic dosing with salmeterol or placebo.
Eur Respir J.
1998;
11
1081-1085
- 34
Leuenberger P, Anderhub H P, Brändli O, Keller R, Knoblauch A, Kuhn M, Perruchoud A P,
Rochat T, Russi E, Villinger B, Zellweger J P.
Management 1997 of chronic obstructive pulmonary disease.
Schweiz Med Wochenschr.
1997;
127
766-782
- 35
Leuenberger P, Schwartz J, Ackermann-Liebrich U, Blaser K, Bolognini G. et al .
Passive Smoking Exposure in Adults and Chronic Respiratory Symptoms (SAPALDIA Study).
Am J Resp Crit Care Med.
1994;
150
1221-1228
- 36
Leuppi J D, Zenhäusern R, Schwarz F, Frey W O, Villiger B.
Bedeutung der Trainingsintensität für die Verbesserung der Ausdauerleistungsfähigkeit
bei Patienten mit chronisch obstruktiven Lungenerkrankungen.
Dtsch Med Wschr.
1998;
123
174-178
- 37
Llewellyn-Jones C G, Harris T AJ, Stockley R A.
Effect of fluticasone propionate on sputum of patients with chronic bronchitis and
emphysema.
Am J Respir Crit Care Med.
1996;
153
616-621
- 38
Lundback B, Lindstrom M, Jonsson E, Anderson S, van Herwaarden C.
Effect of N-acetylcysteine on the decline in lung function in patients with COPD.
Eur Respir J.
1995;
5 (Suppl 15)
895
- 39
Maesen F PV, Smeets J J, Siedsens T JH, Wald F DM, Cornelissen P JG.
Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic
study in patients with chronic obstructive pulmonary disease (COPD).
Eur Respir J.
1995;
8
1506-1513
- 40
Maziak W, Loukides S, Culpitt S, Sullivan P, Kharitonov S A, Barnes P J.
Exhaled nitric oxide in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1998;
157
998-1002
- 41
McEvoy C E, Ensrud K E, Genant H K, Uy W, Griffith J M, Niewoehner D E.
Association between corticosteroid use and vertebral fractures in older men with chronic
obstructive pulmonary disease.
Am J Respir Crit Care Med.
1998;
157
704-709
- 42
McEvoy C E, Niewoehner D E.
Adverse effects of corticosteroid therapy for COPD. A critical review.
CHEST.
1997;
111
732-743
- 43
Paggiaro P L, Dahle R, Bakran I, Frith L, Hollingworth K. et al .
Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate
in patients with chronic obstructive pulmonary disease.
Lancet.
1998;
315
773-780
- 44
Pauwels R A, Löfdahl C-G, Laitinen L A, Schouten J P, Postma D S. et al .
Longterm treatment with inhaled budesonide in persons with mild chronic obstructive
pulmonary disease who continue smoking.
NEJM.
1999;
349
1948-1953
- 45
Perrin C, El Far Y, Vandenbos F, Tamisier R, Dumon M C, Lemoigne F, Mouroux J, Blaive B.
Domiciliary nasal intermittent positive pressure ventilation in severe COPD: effects
on lung function and quality of life.
Eur Respir J.
1997;
10
2835-2839
- 46
Petty T L.
Supportive Therapy in COPD.
CHEST.
1998;
113
256-262S
- 47
Rabe K F, Dent G, Magnussen H.
Theophyllin und selektive Phosphodiesterase-Hemmer in der Therapie obstruktiver Atemwegserkrankungen.
Pneumologie.
1997;
51
303-316
- 48
Renkama T EJ, Schouten J P, Koëter G H, Postma D S.
Effects of long-term treatment with corticosteroids in COPD.
CHEST.
1996;
109
1156-1162
- 49
Rennard S I.
Overview of definitions, epidemiology, and factors influencing its development.
CHEST.
1998;
113
235-241S
- 50
Rennard S I, Serby C W, Ghafouri M, Johnson P A, Friedman M.
Extended therapy with ipratropium is associated with improved lung function in patients
with COPD.
CHEST.
1996;
110
62-70
- 51
Repine J E, Bast A, Lankhorst I. and The Oxidative Stress Study Group .
Oxidative stress in chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1997;
156
341-357
- 52
Russi E W, Stammberger U, Weder W.
Lung volume reduction surgery for emphysema.
Eur Respir J.
1997;
10
208-218
- 53
Sandford A J, Weir T D, Paré P D.
Genetic risk factors for chronic obstructive pulmonary disease.
Eur Respir J.
1997;
10
1380-1391
- 54
Sciurba F C, Rogers R M, Keenan R J, Slivka W A, Gorcsan J, Ferson P F, Holbert M,
Brown M L, Landreneau R J.
Improvement in pulmonary function and elastic recoil after lung-reduction surgery
for diffuse emphysema.
N Engl J Med.
1996;
334
1095-1099
- 55
Senior M R, Anthonisen M R.
Chronic obstructive pulmonary disease (COPD).
Am J Respir Crit Care Med.
1998;
157
S139-S147
- 56
Siafakas N M, Vermeire P, Pride N B, Paoletti P, Gibson J. et al .
Optimal assessment and management of chronic obstructive pulmonary disease (COPD).
ERS-consensus statement.
Eur Respir J.
1995;
8
1398-1420
- 57
Silverman E K, Chapman H R, Drazen J M, Weiss S T, Rosner B. et al .
Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease.
Am J Respir Crit Care Med.
1998;
157
1770-1778
- 58
Sivasothy P, Smith I E, Shneerson J M.
Mask intermittent positive pressure ventilation in chronic hypercapnic respiratory
failure due to chronic obstructive pulmonary disease.
Eur J Respir.
1998;
11
34-40
- 59
Smith C A, Harrison D J.
Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility
to emphysema.
Lancet.
1997;
350
630-633
- 60
Speich R, Boehler A, Weder W.
Lungentransplantation bei fortgeschrittenem Lungenemphysem.
Therapeutische Rundschau.
1999;
56(3)
161-165
- 61
Stammberger U, Bloch K E, Thurnheer R, Bingisser R, Weder W, Russi E W.
Exercise performance and gas exchange after bilateral video-assisted thoracoscopic
lung volume reduction for severe emphysema.
Eur Respir J.
1998;
12
785-792
- 62
Stanescu D, Sanna A, Veriter C, Robert A.
Identification of smokers susceptible to development of chronic airflow limitation.
A 13-year follow up.
CHEST.
1998;
114
416-425
- 63
Thompson W H, Nielson C P, Carvalho P, Charan N B, Crowley J J.
Controlled trial of oral prednisone in outpatients with acute COPD exacerbation.
Am J Respir Crit Care Med.
1996;
154
407-412
- 64
Ukena D, Harnest U, Sakalauskas R, Magyar P, Vetter N. et al .
Comparison of addition of theophylline to inhaled steroid with doubling the dose of
inhaled steroid in asthma.
Eur Respir J.
1997;
10
2754-2760
- 65
Ullmer E, Bolliger C T.
Tabak: Asche, Rauch und „Kohle”.
Schweiz Med Wochenschr.
1999;
129
102-112
- 66
Ullmer E, Solèr M.
Asthma und COPD: Unterschiede und Gemeinsamkeiten.
Internist.
1999;
40
837-843
- 67
Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K.
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary
disease: a randomised controlled trial.
Lancet.
1999;
353
1819-1823
- 68
Wettengel R, Böhning W, Cegla U, Criée C, Fichter J. et al .
Empfehlungen der Deutschen Atemwegsliga zur Behandlung von Patienten mit chronisch
obstructiver Bronchitis und Lungenemphysem.
Med Klinik.
1995;
90
3-7
- 69
Wilson R.
The role of infection in COPD.
CHEST.
1998;
113
242-248S
- 70
Zemp E, Elsasser S, Schindler Ch, Künzli N, Perruchoud A P. et al .
Long-Term Ambient Air Pollution and Respiratory Symptoms in Adults (SAPALDIA Study).
Am J Respir Crit Care Med.
1999;
159
1257-1266
- 71
Zielinski J, Tobiasz M, Hawrylkiewicz I, Sliwinski P, Palasiewicz G.
Effects of long-term oxygen therapy on pulmonary hemodynamics in COPD patients. A
6-year prospective study.
CHEST.
1998;
113
65-70
Prof. Dr. med. André P. Perruchoud
Chefarzt Innere Medizin DIM A Kantonsspital Basel
Petersgraben 4
4031 Basel
Schweiz
